Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (NCT07848880) titled 'A Phase 2 Study to Evaluate the Efficacy and Safety of DR10624 in Subjects With Moderate Hypertriglyceridemia and Diabetic Kidney Disease' on Sept. 24.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Primary Sponsor: Zhejiang Doer Biologics Co., Ltd.

Condition: Hypertriglyceridemia

Intervention: Drug: DR10624 Injection

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: October 2026

Target Sample Size: 315

Countrie...